Ypsomed grows by 21% in the first half of 2025/26 in the core business

Ypsomed continued on its growth trajectory in the first half of the 2025/26 financial year, the Delivery Systems business reached CHF 266.6 million of sales. This represents a 21.0% increase compared to the same period last year. The Delivery Systems EBIT surged to CHF 86.5 million, i.e. an EBIT margin of 32.4%. Including the divested Diabetes Care business and other one-off effects across all business areas, Ypsomed generated half-year sales of CHF 362.7 million and an EBIT of CHF 151.7 million. Following the divestment of the Diabetes Care business, we increase our focus on our core competence and market leading position in self-injection systems.

In the first half of the 2025/26 financial year, Ypsomed completed its transformation into a pure-play injection systems specialist. Following the divestment of the Diabetes Care business, we are now concentrating on our core competency: innovative self-injection systems. To this end, we offer pharmaceutical and biotech companies worldwide the highest quality self-treatment systems – solutions based on the most comprehensive and innovative platform portfolio in our industry.